Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
Some patients treated with dual antiplatelet therapy (DAPT) following acute coronary syndrome (ACS) can still exhibit heightened residual platelet reactivity (HRPR), which is potentially linked to adverse vascular outcomes. Better tailored DAPT strategies are needed to address this medical need. Aim...
Guardado en:
Autores principales: | Nikita Lomakin, Anna Rudakova, Liudmila Buryachkovskaya, Victor Serebruany |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a91ec16800854a1d82afd0cd6c911f1e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention
por: Johny Nicolas, et al.
Publicado: (2020) -
Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
por: Ziwei Xi, et al.
Publicado: (2021) -
Platelet Function Testing and Genotyping for Tailoring Treatment in Complex PCI Patients
por: Athanasios Moulias, et al.
Publicado: (2021) -
Global Thrombosis Test: Occlusion is attributable to shear-induced platelet thrombus formation.
por: Diana Adrienne Gorog, et al.
Publicado: (2021) -
Personalised Approaches to Improving the Effect of Anti-platelet Agents: Where Do We Stand?
por: Lucas C Godoy, et al.
Publicado: (2019)